R2 readies virtual colonoscopy CAD for FDA approval
R2 Technology has unveiled at the RSNA meeting a robust version of computer-aided detection technology programmed to find colon polyps. The company plans to take this latest iteration of CAD, first shown at the 2002 RSNA meeting, to the FDA in next year.
R2 Technology has unveiled at the RSNA meeting a robust version of computer-aided detection technology programmed to find colon polyps. The company plans to take this latest iteration of CAD, first shown at the 2002 RSNA meeting, to the FDA in next year.
"This is going to be one of the hottest CAD areas because it will open up virtual colonoscopy as a modality itself," said R2 CEO Michael Klein.
One reason virtual colonoscopy has not taken off is the difficulty physicians have reading the images, according to Klein. Another reason is that patients still must evacuate the colon before the examination. CAD could help alleviate both problems
CAD for colonoscopy has the potential to speed up the exam and eliminate the need to prep the bowel. R2's virtual colonoscopy system can electronically remove stool from colon scans by distinguishing differences in density between fecal material and polyps.
The system also simplifies interpretation of virtual colonoscopy scans. By taking radiologists directly to areas where suspicious nodules may be present, CAD may trim interpretation time down to a few minutes, Klein said.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
